Risk Factors of Hospital-acquired Thrombocytopenia in Toxicological Intensive Care Unit Thrombocytopenia in Toxicological Intensive Care Unit
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 10 No. 3 (2020),
27 September 2020
Background: Platelet count is a readily available biomarker predicting disease severity and risk of mortality in the intensive care units (ICU). This study aims to describe the frequency, to assess the risk factors, and to evaluate the impact of thrombocytopenia on patient outcomes in a Toxicological ICU (TICU).
Methods: In this prospective observational Cohort study, we enrolled 184 patients admitted to our TICU from October 1st, 2019, to August 23rd, 2020. Mild/moderate and severe thrombocytopenia were defined as at least one platelet counts less than 150×103/µL and 50×103/µL during the ICU stay, respectively.
Results: Of 184 enrolled patients, 45.7% had mild to moderate thrombocytopenia and 5.4% had severe thrombocytopenia. Old age (OR: 1.042, 95%CI: 1.01-1.075, P=0.01), male gender (OR: 4.348, 95%CI: 1.33-14.22, P=0.015), increased international normalized ratio (INR) levels (OR: 3.72, 95%CI: 1.15-112, P=0.028), and administration of some medications including heparin (OR: 3.553, 95%CI: 1.11-11.36, P=0.033), antihypertensive drugs (OR: 2.841, 95%CI: 1.081-7.471, P=0.034), linezolid (OR: 13.46, 95%CI: 4.75-38.13, P<0.001), erythromycin (OR: 19.58, 95%CI: 3.23-118.86, P=0.001), and colistin (OR: 10.29, 95% CI 1.44-73.69, P=0.02) were the risk factors of hospital-acquired thrombocytopenia. The outcomes of patients with normal platelet count were significantly better than those who developed thrombocytopenia (P<0.001).
Conclusion: We found that thrombocytopenia could develop in almost 50% of patients admitted to TICU, which is associated with poor prognosis. Additionally, the platelet counts should be closely monitored to administer some medications (heparin, antihypertensive drug, and linezolid), especially in old patients.
- Thrombocytopenia, Poisoning, Intensive Care Unit (ICU), Patient Outcome Assessment, Risk factors
How to Cite
Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency and clinical significance of thrombocytopenia complicating critical illness: A systematic review. Chest. 2011; 139(2):271-8. [DOI:10.1378/chest.10-2243] [PMID]
Moreau D, Timsit JF, Vesin A, Garrouste-Orgeas M, de Lassence A, Zahar JR, et al. Platelet count decline: An early prognostic marker in critically ill patients with prolonged ICU stays. Chest. 2007; 131(6):1735-41. [DOI:10.1378/chest.06-2233] [PMID]
Vanderschueren S, De Weerdt A, Malbrain M, Vankersschaever D, Frans E, Wilmer A, et al. Thrombocytopenia and prognosis in intensive care. Critical Care Medicine. 2000; 28(6):1871-6. [DOI:10.1097/00003246-200006000-00031] [PMID]
Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG. Thrombocytopenia in patients in the medical intensive care unit: Bleeding prevalence, transfusion requirements, and outcome. Critical Care Medicine. 2002; 30(8):1765-71. [DOI:10.1097/00003246-200208000-00015] [PMID]
Venkata C, Kashyap R, Farmer JC, Afessa B. Thrombocytopenia in adult patients with sepsis: Incidence, risk factors, and its association with clinical outcome. Journal of Intensive Care. 2013; 1(1):9. [DOI:10.1186/2052-0492-1-9] [PMID] [PMCID]
Khurana D, Deoke SA. Thrombocytopenia in critically Ill patients: clinical and laboratorial behavior and its correlation with short-term outcome during hospitalization. Indian Journal Of Critical Care Medicine. 2017; 21(12):861. [DOI:10.4103/ijccm.IJCCM_279_17] [PMID] [PMCID]
Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clinica Chimica Acta. 2020; 506:145-8. [DOI:10.1016/j.cca.2020.03.022] [PMID] [PMCID]
Kinasewitz GT, et al., Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Critical Care. 2004; 8(2):R82-90. [DOI:10.1186/cc2459] [PMID] [PMCID]
Stéphan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A. Thrombocytopenia in a surgical ICU. Chest. 1999; 115(5):1363-70. [DOI:10.1378/chest.115.5.1363] [PMID]
Nijsten MW, ten Duis HJ, Zijlstra JG, Porte RJ, Zwaveling JH, Paling JC, et al. Blunted rise in platelet count in critically ill patients is associated with worse outcome. Critical Care Medicine. 2000; 28(12):3843-6. [DOI:10.1097/00003246-200012000-00017] [PMID]
Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison’s principles of internal medicine. 20th ed. New York: McGraw-Hill Education; 2018.
Arnold DM, Cuker A. Approach to the adult with unexplained thrombocytopenia [Internet]. [Updated: July 2020]. Available from: https://www.lib.utdo.ir/contents/approach-to-the-adult-with-unexplained-thrombocytopenia/print?search=thrombocutopenia&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.
Hoffman RS, Howland MA, Lewin N, Nelson L, Goldfrank L. Goldfrank’s Toxicologic Emergencies. 10th ed. New York: McGraw-Hill Education; 2014.
Baughman RP, Lower EE, Flessa HC, Tollerud DJ. Thrombocytopenia in the intensive care unit. Chest. 1993; 104(4):1243-7. [DOI:10.1378/chest.104.4.1243] [PMID]
Hine LK, Gerstman BB, Wise RP, Tsong Y. Mortality resulting from blood dyscrasias in the United States, 1984. The American Journal of Medicine. 1990. 88(2):151-3. [DOI:10.1016/0002-9343(90)90465-P]
Bonfiglio MF, Traeger SM, Kier KL, Martin BR, Hulisz DT, Verbeck SR. Thrombocytopenia in intensive care patients: A comprehensive analysis of risk factors in 314 patients. The Annals of Pharmacotherapy. 1995; 29(9):835-42. [DOI:10.1177/106002809502900901] [PMID]
Crowther MA, Cook DJ, Meade MO, Griffith LE, Guyatt GH, Arnold DM, et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Journal of Critical Care. 2005; 20(4):348-53. [DOI:10.1016/j.jcrc.2005.09.008] [PMID]
Fountain EM, Arepally GM. Etiology and complications of thrombocytopenia in hospitalized medical patients. Journal of Thromb Thrombolysis. 2017; 43(4):429-36. [DOI:10.1007/s11239-016-1467-8] [PMID]
Hanai Y, Matsuo K, Ogawa M, Higashi A, Kimura I, Hirayama S, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. Journal of Infection and Chemotherapy. 2016; 22(8):536-42. [DOI:10.1016/j.jiac.2016.05.003] [PMID]
Silczuk A, Habrat B. Alcohol-induced thrombocytopenia: Current review. Alcohol. 2020; 86:9-16. [DOI:10.1016/j.alcohol.2020.02.166] [PMID]
Andersen GO, Ritland S. Life threatening intoxication with sodium valproate. Journal of Toxicology: Clinical Toxicology. 1995; 33(3):279-84. [DOI:10.3109/15563659509018000] [PMID]
Gafter, U., et al., Thrombocytopenia, eosinophilia, and ranitidine. Annals of internal medicine, 1987. 106(3): p. 477-477. [DOI:10.7326/0003-4819-106-3-477_1] [PMID]
Fuortes LJ, Weismann DN, Graeff ML, Bale JF Jr, Tannous R, Peters C. Immune thrombocytopenia and elemental mercury poisoning. Journal of Toxicology: Clinical Toxicology. 1995; 33(5):449-55. [DOI:10.3109/15563659509013753] [PMID]
Kao WF, Hung DZ, Tsai WJ, Lin KP, Deng JF. Podophyllotoxin intoxication: Toxic effect of Bajiaolian in herbal therapeutics. Human & Experimental Toxicology. 1992; 11(6):480-7. [DOI:10.1177/096032719201100607] [PMID]
Afolabi OK, Oyewo EB, Adeleke GE, Badmus JA, Wusu AD. Mitigation of aluminium phosphide-induced hematotoxicity and ovarian oxidative damage in Wistar rats by Hesperidin. American Journal of Biochemistry. 2019; 9(1):7-16. [DOI:10.5923/j.ajb.20190901.03]
Priziola JL, Smythe MA, Dager WE. Drug-induced thrombocytopenia in critically ill patients. Critical Care Medicine. 2010; 38(Suppl 6):S145-54. [DOI:10.1097/CCM.0b013e3181de0b88] [PMID]
Jones CI. Platelet function and ageing. Mammalian genome. 2016; 27(7-8):358-66. [DOI:10.1007/s00335-016-9629-8] [PMID] [PMCID]
eHealthMe. Will you have Jaundice with methadone hydrochloride? [Internet] [cited: 2020 september 9]; Available from: https://www.ehealthme.com/ds/methadone-hydrochloride/thrombocytopenia/.
Sanidas EA, Tzanis G, Papadopoulos D, Barbetseas J, Papademetriou V. Olmesartan worsening known thrombocytopenia. A rare side effect of antihypertensive drugs. Hellenic Journal of Cardiology. 2017; 58(1):96-7. [DOI:10.1016/j.hjc.2017.01.020] [PMID]
Patel DK, Bilkha N, Schnee D. Angiotensin II type 1 receptor blocker-induced immune thrombocytopenia: A case report. Journal of Medical Case Reports. 2013; 7(1):183. [DOI:10.1155/2013/653925] [PMID] [PMCID]
Patriarcheas V, Pikoulas A, Kostis M, Charpidou A, Dimakakos E. Heparin-induced thrombocytopenia: Pathophysiology, diagnosis and management. Cureus. 2020; 12(3):e7385. [DOI:10.7759/cureus.7385] [PMID] [PMCID]
McKenzie DS, Anuforo J, Morgan J, Neculiseanu E. Successful use of intravenous immunoglobulin g to treat refractory heparin-induced thrombocytopenia with thrombosis complicating peripheral blood stem cell harvest. Journal of Investigative Medicine High Impact Case Reports. 2018; 6:2324709618755414. [DOI:10.1177/2324709618755414] [PMID] [PMCID]
Solomon HM, Randall JR, Simmons VL. Heparin-induced increase in the international normalized ratio. Responses of 10 commercial thromboplastin reagents. American Journal of Clinical Pathology. 1995; 103(6):735-9. [DOI:10.1093/ajcp/103.6.735] [PMID]
Kupeli S. Colistin-related thrombocytopenia. Platelets. 2015; 26(8):812-3. [DOI:10.3109/09537104.2015.1004044] [PMID]
Grim SA, Rene L, Gupta S, Clark NM. Safety of linezolid in patients with baseline thrombocytopenia. Journal of Antimicrobial Chemotherapy. 2008; 62(4):850-1. [DOI:10.1093/jac/dkn285] [PMID]
Matsumoto K, Takeda Y, Takeshita A, Fukunaga N, Shigemi A, Yaji K, et al. Renal function as a predictor of linezolid-induced thrombocytopenia. International Journal of Antimicrobial Agents. 2009; 33(1):98-9. [DOI:10.1016/j.ijantimicag.2008.07.002] [PMID]
Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O'Grady M, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrobial Agents and Chemotherapy. 2003; 47(9):2775-80. [DOI:10.1128/AAC.47.9.2775-2780.2003] [PMID] [PMCID]
Watkins VS, Polk RE, Stotka JL. Drug interactions of macrolides: Emphasis on dirithromycin. The Annals of Pharmacotherapy. 1997; 31(3):349-56. [DOI:10.1177/106002809703100314] [PMID]
Henry-Edwards S, Gowing L, White J, Ali R, Bell J, Brough R, et al. Possible drug interactions with methadone: Appendix 1. In: Clinical guidelines and procedures for the use of methadonein the maintenance treatment of opioid dependence. Australian Government Department of Health and Ageing: Publications Production Unit; 2003. file:///C:/Users/Negah-11/Desktop/1512351159_National%20Guidelines%20and%20Procedures%20for%20the%20use%20of%20%20methadone.pdf
Iribarne C, Berthou F, Baird S, Dréano Y, Picart D, Bail JP, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chemical Research in Toxicology. 1996; 9(2):365-73. [DOI:10.1021/tx950116m] [PMID]
Vandijck DM, Blot SI, De Waele JJ, Hoste EA, Vandewoude KH, Decruyenaere JM. Thrombocytopenia and outcome in critically ill patients with bloodstream infection. Heart & Lung. 2010; 39(1):21-6. [DOI:10.1016/j.hrtlng.2009.07.005] [PMID]
- Abstract Viewed: 22 times
- pdf Downloaded: 20 times